AUTHORS
Michelle Rudshteyn Korostin, MD, Jonathan Feld, MD2, Tianxiang Sheng, MSc3, Shambavi Richard, MD4, Adriana Rossi, MD5, Larysa Sanchez, MD6, Joshua Richter I, MD7, Santiago Thibaud, MD8, Cesar Rodriguez Valdes, MD9, Zachary M. Avigan, MD, MHS10, Shafinaz Hussein I, MD11, Jane Houldsworth, PhD12, Meenakshi Mehrotra, PhD13, Amir Horowitz I, Ph D14, Sundar Jagannath, M.D.15, Samir Parekh, MD16, Lewis R Silverman, MD17
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, Florida, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Health System at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 Icahn School of Medicine at Mount Sinai, New York, New York, United States
14 Icahn School of Medicine at Mount Sinai, New York, New York, United States, Icahn School of Medicine at Mount Sinai, New York, New York, United States
15 Icahn School of Medicine at Mount Sinai, New York, New York, United States
16 Icahn School of Medicine at Mount Sinai, New York, New York, United States
17 Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
Background:
Expanded clonal T-cell populations with a large granular lymphocyte (LGL) phenotype have been described in patients (pts) with myelodysplastic syndrome (MDS) and a broad range of hematologic and autoimmune disorders and are associated with pronounced cytopenias. MDS pts with a coexisting LGL clone(s) have been treated with weekly IVIG (500mg/kg) yielding a high response rate (JM Feld, Blood, 2019). Hematologic toxicities are a recognized complication of T-cell redirecting therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell therapy (CAR-T) and bispecific antibodies (bsAbs). Expansion of activated CD57+ T-cell clones, distinct from de novo malignant LGL leukemia, has been identified following CAR-T and may represent a cause of prolonged cytopenias, potentially related to an inflammatory state. We investigated IVIG as a novel strategy to mitigate prolonged cytopenias following T-cell redirecting therapy.
Methods:
We retrospectively reviewed a single-center series of MM pts treated with ≥4 weekly doses of IVIG (350-500 mg/kg/day) for prolonged cytopenias after BCMA-directed CAR-T (n=14) or bsAb (n=9). In pts with improvement, IVIG frequency was de-escalated to bi-/tri-weekly, then monthly to maintain response or for ongoing hypogammaglobulinemia. T-cell clonality was identified by T-cell receptor gene rearrangement (TRG and TRB) sequencing (TCR-seq) and LGL phenotype by flow cytometry. No STAT3, STAT5, or other LGL-associated mutations were detected among the 23 pts, supporting a reactive clonal LGL process.
Cytopenias were graded per CTCAE v5.0. Primary deficient lineage was the cell line with the greatest deficit from normal or requiring transfusion/growth factor support. Hematologic improvement (HI) was assessed after the initial weekly doses per IWG 2006 MDS criteria; ongoing responses <8 weeks were considered provisional. Outcomes were summarized as proportions with exact 95% confidence intervals and medians with ranges, compared by two-sided Fisher exact tests, Wilcoxon rank-sum tests, and exact Wilcoxon signed-rank tests. Given the small sample and multiple exploratory endpoints, p-values were interpreted descriptively.
Results:
Included CAR-T pts had significant, prolonged cytopenias, starting weekly IVIG a median of 185 days (~6 months; range 47–989) after CAR-T infusion. A T-cell clone by TCR-seq was present in 11/14 (79%) pts. All pts had at least 1 grade ≥3 (G3) cytopenia, with median ANC 0.6, platelets 53, and Hgb 10.1. BsAb pts (7/9 TCR-seq+) had ≥G3 neutropenia in 7 of 9 pts (median ANC 0.6) and ≥G3 thrombocytopenia in 2 pts. Pts received a median of 6 weekly doses of IVIG in the CAR-T (range 4-18) and bsAb (range 4-15) cohorts. Bi-/tri-weekly dosing extended a median of 2 months, then monthly in most pts.
Ten of 14 CAR-T pts (71%; 95% CI, 42–92%) achieved HI in ≥1 lineage, 7 (50%; 23–77%) in the primary deficient lineage, and 4 in >1 lineage. ≥G3 neutropenia resolved in 9/12 pts, thrombocytopenia in 4/7, and anemia in 3/3. Among CAR-T pts receiving growth factor prior to IVIG, 4/8 discontinued G-CSF, 1/5 a TPO receptor agonist, and 2/2 an ESA. All 4 pts with RBC and/or platelet transfusion-dependence became transfusion-independent, and a hemolytic response occurred in 4/4 evaluated pts. Four of 9 bsAb pts (44%; 14–79%) met HI criteria, all HI-N; 1 response was ongoing at 2 weeks. Among responders the median time to response from first IVIG dose was 5.4 weeks (range 2-16) in CAR-T pts and 5.9 weeks (range 3.6-16) in bsAb pts. In CAR-T pts, response occurred in 9/11 pts with a T-cell clone vs 1/3 without; in bsAb pts, 3/7 and 1/2 (NS). Paired flow data in CAR-T pts showed a decline in the CD57+ LGL population (% of CD45+ cells) among responders, with no reduction in non-responders. Further testing in both cohorts showed 4 had CCUS, 1 intermediate-risk MDS, and 1 bi-allelic TP53-mutated high-risk MDS. Neither pt with underlying MDS responded to IVIG, while the 4 pts with CCUS showed HI.
Conclusions:
Hematologic response was observed after weekly IVIG in pts with prolonged cytopenias following T-cell redirecting therapy. Clinically, IVIG can reduce transfusion burden, allow withdrawal of growth factor, and enable continued myeloma therapy. These findings support further evaluation of IVIG as a relatively non-toxic strategy to improve cytopenias; analysis of the underlying clonal T-cell expansion and mechanism is ongoing.
DISCLOSURES
Michelle Rudshteyn Korostin, MD: No relevant conflicts of interest to declare.